The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus

Research output: Contribution to journalArticle

Abstract

AIM: To evaluate if the addition of Berberis aristata/Silybum marianum (Berberol(®)) leads to a reduction of insulin dose and to an improvement of glycemic control in patients with type 1 diabetes mellitus.

MATERIAL AND METHODS: 85 type 1 diabetic patients were enrolled and randomized to take placebo or B. aristata/S. marianum 588/105 mg, 1 tablet at lunch and 1 tablet at dinner, for six months. We evaluated if there was a reduction of insulin dose necessary to reach an adequate glycemic control. We also evaluated at the study start, and after 6 months: body mass index (BMI), glycated hemoglobin, fasting plasma glucose (FPG), post-prandial glucose (PPG), lipid profile.

RESULTS: We observed a reduction of total insulin consumption in B. aristata/S. marianum, both compared to baseline and to placebo. Regarding insulin administration at meals, we recorded that the group treated with B. aristata/S. marianum used less insulin at meals, and at bedtime. Glycated hemoglobin decreased with B. aristata/S. marianum compared to baseline, but not compared to placebo. There was a decrease of FPG, and PPG with B. aristata/S. marianum both compared to baseline and to placebo. Regarding lipid profile, we recorded a decrease of total cholesterol, triglycerides, and LDL-cholesterol and an increase of HDL-cholesterol with B. aristata/S. marianum, both compared to baseline and to placebo.

CONCLUSIONS: The addition of B. aristata/S. marianum to insulin therapy in patients with type 1 diabetes mellitus leads to a reduction of the insulin dose necessary to have an adequate glycemic control.

Original languageEnglish
Pages (from-to)1091-5
Number of pages5
JournalClinical Nutrition
Volume35
Issue number5
DOIs
Publication statusPublished - Oct 2016

Fingerprint

Berberis
Milk Thistle
Type 1 Diabetes Mellitus
Insulin
Meals
Placebos
Glucose
Glycosylated Hemoglobin A
Therapeutics
Tablets
Fasting
Lipids
Lunch
LDL Cholesterol
HDL Cholesterol
Triglycerides
Body Mass Index
Cholesterol

Keywords

  • Journal Article

Cite this

@article{0cb4d1dfe9ea485293334b256d371f83,
title = "The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus",
abstract = "AIM: To evaluate if the addition of Berberis aristata/Silybum marianum (Berberol({\circledR})) leads to a reduction of insulin dose and to an improvement of glycemic control in patients with type 1 diabetes mellitus.MATERIAL AND METHODS: 85 type 1 diabetic patients were enrolled and randomized to take placebo or B. aristata/S. marianum 588/105 mg, 1 tablet at lunch and 1 tablet at dinner, for six months. We evaluated if there was a reduction of insulin dose necessary to reach an adequate glycemic control. We also evaluated at the study start, and after 6 months: body mass index (BMI), glycated hemoglobin, fasting plasma glucose (FPG), post-prandial glucose (PPG), lipid profile.RESULTS: We observed a reduction of total insulin consumption in B. aristata/S. marianum, both compared to baseline and to placebo. Regarding insulin administration at meals, we recorded that the group treated with B. aristata/S. marianum used less insulin at meals, and at bedtime. Glycated hemoglobin decreased with B. aristata/S. marianum compared to baseline, but not compared to placebo. There was a decrease of FPG, and PPG with B. aristata/S. marianum both compared to baseline and to placebo. Regarding lipid profile, we recorded a decrease of total cholesterol, triglycerides, and LDL-cholesterol and an increase of HDL-cholesterol with B. aristata/S. marianum, both compared to baseline and to placebo.CONCLUSIONS: The addition of B. aristata/S. marianum to insulin therapy in patients with type 1 diabetes mellitus leads to a reduction of the insulin dose necessary to have an adequate glycemic control.",
keywords = "Journal Article",
author = "Giuseppe Derosa and Angela D'Angelo and Pamela Maffioli",
note = "Copyright {\circledC} 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.",
year = "2016",
month = "10",
doi = "10.1016/j.clnu.2015.08.004",
language = "English",
volume = "35",
pages = "1091--5",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus

AU - Derosa, Giuseppe

AU - D'Angelo, Angela

AU - Maffioli, Pamela

N1 - Copyright © 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

PY - 2016/10

Y1 - 2016/10

N2 - AIM: To evaluate if the addition of Berberis aristata/Silybum marianum (Berberol(®)) leads to a reduction of insulin dose and to an improvement of glycemic control in patients with type 1 diabetes mellitus.MATERIAL AND METHODS: 85 type 1 diabetic patients were enrolled and randomized to take placebo or B. aristata/S. marianum 588/105 mg, 1 tablet at lunch and 1 tablet at dinner, for six months. We evaluated if there was a reduction of insulin dose necessary to reach an adequate glycemic control. We also evaluated at the study start, and after 6 months: body mass index (BMI), glycated hemoglobin, fasting plasma glucose (FPG), post-prandial glucose (PPG), lipid profile.RESULTS: We observed a reduction of total insulin consumption in B. aristata/S. marianum, both compared to baseline and to placebo. Regarding insulin administration at meals, we recorded that the group treated with B. aristata/S. marianum used less insulin at meals, and at bedtime. Glycated hemoglobin decreased with B. aristata/S. marianum compared to baseline, but not compared to placebo. There was a decrease of FPG, and PPG with B. aristata/S. marianum both compared to baseline and to placebo. Regarding lipid profile, we recorded a decrease of total cholesterol, triglycerides, and LDL-cholesterol and an increase of HDL-cholesterol with B. aristata/S. marianum, both compared to baseline and to placebo.CONCLUSIONS: The addition of B. aristata/S. marianum to insulin therapy in patients with type 1 diabetes mellitus leads to a reduction of the insulin dose necessary to have an adequate glycemic control.

AB - AIM: To evaluate if the addition of Berberis aristata/Silybum marianum (Berberol(®)) leads to a reduction of insulin dose and to an improvement of glycemic control in patients with type 1 diabetes mellitus.MATERIAL AND METHODS: 85 type 1 diabetic patients were enrolled and randomized to take placebo or B. aristata/S. marianum 588/105 mg, 1 tablet at lunch and 1 tablet at dinner, for six months. We evaluated if there was a reduction of insulin dose necessary to reach an adequate glycemic control. We also evaluated at the study start, and after 6 months: body mass index (BMI), glycated hemoglobin, fasting plasma glucose (FPG), post-prandial glucose (PPG), lipid profile.RESULTS: We observed a reduction of total insulin consumption in B. aristata/S. marianum, both compared to baseline and to placebo. Regarding insulin administration at meals, we recorded that the group treated with B. aristata/S. marianum used less insulin at meals, and at bedtime. Glycated hemoglobin decreased with B. aristata/S. marianum compared to baseline, but not compared to placebo. There was a decrease of FPG, and PPG with B. aristata/S. marianum both compared to baseline and to placebo. Regarding lipid profile, we recorded a decrease of total cholesterol, triglycerides, and LDL-cholesterol and an increase of HDL-cholesterol with B. aristata/S. marianum, both compared to baseline and to placebo.CONCLUSIONS: The addition of B. aristata/S. marianum to insulin therapy in patients with type 1 diabetes mellitus leads to a reduction of the insulin dose necessary to have an adequate glycemic control.

KW - Journal Article

U2 - 10.1016/j.clnu.2015.08.004

DO - 10.1016/j.clnu.2015.08.004

M3 - Article

C2 - 26384091

VL - 35

SP - 1091

EP - 1095

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 5

ER -